What are the side effects of Quizartinib?

Quizartinib is an oral, highly effective type II inhibitor of FLT3, specifically developed to treat adult patients with FLT3-ITD-positive acute myeloid leukemia. It inhibits FLT3kinase activity and prevents receptor autophosphorylation, thereby inhibiting downstream FLT3 receptor signaling and blocking FLT3-ITD-dependent cell proliferation. Although quizartinib has shown good efficacy in clinical trials, its use may also bring about a series of side effects.

Patients may experience a variety of side effects while taking quizartinib. Common side effects include nausea, vomiting, stomach pain, upset stomach, diarrhea and digestive problems such as loss of appetite. Additionally, patients may suffer from fungal infections, sepsis, stinging eyes, nosebleeds, cold symptoms, and herpes infections. Some patients may experience difficulty sleeping, low levels of platelets in the blood, electrolyte imbalances, and abnormal liver function tests. Abnormalities in the electrocardiogram or ECG may also occur, as well as low blood cell counts, with symptoms such as fever, chills, tiredness, mouth sores, skin sores, easy bruising, abnormal bleeding, pale skin, cold hands and feet, and shortness of breath.

It is important to note that quizartinib may cause serious heart problems, especially when used with certain other drugs. Patients should contact their doctor immediately if they experience symptoms such as irregular heartbeat, dizziness, or feeling like they are about to pass out. In addition, allergic reactions are also a risk that need to be alerted during the use of Quizartinib. If signs of allergies such as hives, difficulty breathing, swelling of the face, lips, tongue, or throat occur, patients should seek emergency medical help immediately.

In short, although quizartinib provides a new treatment option for patients with FLT3-ITDpositive acute myeloid leukemia, patients should pay close attention to their own conditions during use and report any abnormal symptoms to their doctors in a timely manner so that doctors can adjust the treatment plan according to the actual situation to ensure the safety and effectiveness of the treatment.

xa0

Reference: https://www.drugs.com/mtm/quizartinib.html